ATE406915T1 - Mittel zur regulierung der sekretion von pankreassaft mit einem lpa-rezeptor-regler - Google Patents

Mittel zur regulierung der sekretion von pankreassaft mit einem lpa-rezeptor-regler

Info

Publication number
ATE406915T1
ATE406915T1 AT02746091T AT02746091T ATE406915T1 AT E406915 T1 ATE406915 T1 AT E406915T1 AT 02746091 T AT02746091 T AT 02746091T AT 02746091 T AT02746091 T AT 02746091T AT E406915 T1 ATE406915 T1 AT E406915T1
Authority
AT
Austria
Prior art keywords
pancreatic juice
secretion
regulating
agent
lpa receptor
Prior art date
Application number
AT02746091T
Other languages
English (en)
Inventor
Shinji Nakade
Hiroshi Saga
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Application granted granted Critical
Publication of ATE406915T1 publication Critical patent/ATE406915T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Non-Alcoholic Beverages (AREA)
AT02746091T 2001-07-17 2002-07-16 Mittel zur regulierung der sekretion von pankreassaft mit einem lpa-rezeptor-regler ATE406915T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001216133 2001-07-17

Publications (1)

Publication Number Publication Date
ATE406915T1 true ATE406915T1 (de) 2008-09-15

Family

ID=19050646

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02746091T ATE406915T1 (de) 2001-07-17 2002-07-16 Mittel zur regulierung der sekretion von pankreassaft mit einem lpa-rezeptor-regler

Country Status (7)

Country Link
US (2) US20040171582A1 (de)
EP (1) EP1415667B1 (de)
JP (1) JPWO2003007991A1 (de)
AT (1) ATE406915T1 (de)
DE (1) DE60228732D1 (de)
ES (1) ES2312588T3 (de)
WO (1) WO2003007991A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
WO2004002530A1 (ja) * 2002-06-26 2004-01-08 Ono Pharmaceutical Co., Ltd. 慢性疾患治療剤
EP1553075B1 (de) 2002-10-03 2013-08-14 Ono Pharmaceutical Co., Ltd. Lpa-rezeptor-antagonisten
WO2005012269A1 (ja) * 2003-08-05 2005-02-10 Ajinomoto Co., Inc. 新規アゾール化合物
WO2005064332A1 (ja) * 2003-12-26 2005-07-14 Ono Pharmaceutical Co., Ltd. 高活性型リゾホスファチジン酸およびそれを用いたスクリーニング方法
US20090068281A1 (en) * 2005-03-29 2009-03-12 Koji Toyomura Composition, Functional Food and Pharmaceutical Composition for Improvement in Obesity
US9186343B2 (en) * 2007-12-26 2015-11-17 Nanoveson, Llc Nanoveso™: treatment, biomarkers and diagnostic tests for liver diseases and comorbid diseases
EP2324852B1 (de) 2008-08-07 2015-07-08 Nagasaki University Therapeutischer oder prophylaktischer wirkstoff für generalisiertes schmerzsyndrom
WO2010068775A2 (en) 2008-12-11 2010-06-17 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
IN2012DN00754A (de) 2009-08-04 2015-06-19 Amira Pharmaceuticals Inc
GB2474120B (en) * 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
US8975235B2 (en) 2011-03-20 2015-03-10 Intermune, Inc. Lysophosphatidic acid receptor antagonists
WO2012138797A1 (en) 2011-04-05 2012-10-11 Amira Pharmaceuticals, Inc. 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders
WO2015152412A1 (ja) * 2014-04-04 2015-10-08 国立大学法人大阪大学 リゾリン脂質受容体を活性化する物質を含有する薬剤送達促進剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002500041A (ja) * 1997-12-30 2002-01-08 エヌピーエス アレリックス コーポレーション 炎症応答に関与するリゾ脂質受容体の同定
US6380177B1 (en) * 1999-06-25 2002-04-30 Atairgin Technologies, Inc. LPA analogs as agonists of the Edg2 LPA receptor
WO2001060819A1 (fr) * 2000-02-18 2001-08-23 Kirin Beer Kabushiki Kaisha Nouveaux composes d'isoxazole et de thiazole et leur utilisation en tant que medicaments
US6875757B2 (en) * 2000-03-17 2005-04-05 University Of Tennessee Research Foundation LPA receptor agonists and antagonists and methods of use
EP1364659B1 (de) * 2001-02-08 2009-11-11 Ono Pharmaceutical Co., Ltd. Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors

Also Published As

Publication number Publication date
EP1415667A1 (de) 2004-05-06
ES2312588T3 (es) 2009-03-01
EP1415667A4 (de) 2006-04-19
US20080234230A1 (en) 2008-09-25
WO2003007991A1 (fr) 2003-01-30
DE60228732D1 (de) 2008-10-16
US20040171582A1 (en) 2004-09-02
JPWO2003007991A1 (ja) 2004-11-04
EP1415667B1 (de) 2008-09-03

Similar Documents

Publication Publication Date Title
ATE406915T1 (de) Mittel zur regulierung der sekretion von pankreassaft mit einem lpa-rezeptor-regler
DE60321318D1 (de) Gewinnung von delta-9 tetrahydrocannabinol
UA40587C2 (uk) Метансульфонат (е)-3-[2-h-бутил-1{(4-карбоксифеніл)метил}-1н-імідазол-5-іл]-2-(2-тієніл)метил-2-пропенової кислоти, спосіб його одержання, фармацевтична композиція на його основі
NZ514203A (en) Stabilized bromine solutions, method of manufacture and uses thereof for biofouling control
BR0207325A (pt) Métodos terapêuticos para doenças associadas com expressão diminuìda de gene de aop-1 ou aop-1
PL285591A1 (en) Method for manufacturing new imidazolilalkenecrbxylic acids
TW200618509A (en) System, apparatus, computer program product and method for controlling terminal output power
BR0011891A (pt) Composto, composição farmacêutica, uso de um composto, métodos para tratamento de uma doença ou condição mediada pelo hpparso , para diminuir triglicerìdios em um paciente, para tratar a diabete do tipo 2, diminuir a resistência à insulina ou abaixar a pressão sanguìnea em um paciente, para diminuir os nìveis de fribogênio em um paciente, para diminuir o ldlc em um paciente e para mudar o tamanho da partìcula do ldl denso pequeno para denso normal em um paciente, e , uso de uma agonista hpparso
AU640417B2 (en) Substituted 5-((tetrazolyl)alkenyl)imidazoles
BR9712637A (pt) Método e equipamento para efetuar um movimento rápido para baixo em um sistema de controle de potência da ligação enviada de um telefone celular
EP0437103A3 (de) Substituierte 5-(Alkyl)-carboxamid-Imidazole
WO2003103697A3 (en) USE OF COMPOUNDS HAVING GIP ACTIVITY IN THE TREATMENT OF DISORDERS ASSOCIATED WITH ABNORMAL CELL LOSS AND / OR IN THE TREATMENT OF OBESITY
UA49880C2 (uk) Дигідрат ерпоcартану, фармацевтична композиція, спосіб отримання твердої дозованої форми, спосіб блокування рецепторів ангіотензину іі
HUT56077A (en) Process for producing n-(imidazolyl-alkyl)-alanyl derivatives with substituents and pharmaceutical compositions containing them as active components
MY129355A (en) Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists
WO2003064452A3 (en) Method for the preparation of highly branched polypeptides
WO2004041208A3 (en) Controlled absorption of mixed thyroyd hormone formulations
WO2005051401A3 (en) Prevention and treatment of hypertensive heart diseases by the selective estrogens 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol and 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol
Ojeda et al. Release of prostaglandin E2 from the hypothalamus depends on extracellular Ca2+ availability: relation to LHRH release
EP1541171A4 (de) Mittel zur behandlung von diabetes mellitus
AU2003275495A8 (en) Methods of treating injuries of the nervous system associated with hemorrhage
Jovanovic et al. Analysis of factors influencing chronic renal failure progression
SE9404192D0 (sv) New process
Samuelsson-Almen et al. Pituitary adenylate cyclase-activating polypeptide-and vip-induced activation of adenylate cyclase in the porcine non-pigmented ciliary epithelium: effects of antagonists
Rihoux et al. G proteins as biological targets for anti-allergic drugs?

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties